{"id":"cioteronel","rwe":[],"tags":[{"label":"cioteronel","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cyoctol","offLabel":[],"synonyms":["cioteronel","cyoctol","exandron"],"timeline":[],"approvals":[],"brandName":"Cyoctol","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"cioteronel","explanation":"Think of it like a key fitting into a lock. Cioteronel is the key that blocks the action of a specific protein, which is involved in a particular process in the body. By blocking this protein, cioteronel can help to treat certain conditions.","oneSentence":"Cioteronel works by binding to and inhibiting a specific protein target, although the exact target is unknown.","technicalDetail":"Cioteronel is a competitive inhibitor of the unknown protein target, with a binding affinity that is not yet fully characterized."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cioteronel","title":"Cioteronel","extract":"Cioteronel is a nonsteroidal antiandrogen (NSAA) that was never marketed. It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia, and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3712","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CIOTERONEL","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://en.wikipedia.org/wiki/Cioteronel","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:02:45.716428","biosimilars":[],"competitors":[],"genericName":"cioteronel","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"1RTH95874Z","CHEBI":"CHEBI:135030","INN_ID":"6786","UMLSCUI":"C0625429","ChEMBL_ID":"CHEMBL2104105","KEGG_DRUG":"D03515","PUBCHEM_CID":"55994","SNOMEDCT_US":"96375007","MESH_SUPPLEMENTAL_RECORD_UI":"C046699"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cioteronel is a small molecule drug in the cioteronel class, developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are unknown. Cioteronel has not been approved by the FDA for any indications. The commercial status of cioteronel is unclear, with no information available on generic manufacturers or patent status. Further research is needed to determine the safety and efficacy of cioteronel.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}